 |
|
|
|
|
|
|
|
 |
Results for 'Cancer Overview (Pipeline Insight)' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
100 % |
Vardenafil: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
46 % |
Docetaxel: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
46 % |
Topotecan: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
45.5 % |
Gatifloxacin: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
45.5 % |
New Concepts in Cancer Therapeutics
|
December 2005 |
£1665 |
42.5 % |
Commercial Insight: Top 20 Cancer Therapy Brands - Sales of targeted therapies overtake cytotoxics in 2006
|
July 2007 |
£7600 |
42.5 % |
Targeted Cancer Therapies Markets
Sector Snapshot
|
January 2006 |
£250 |
42 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£4715 |
42 % |
Analytical Tool: Prostate Cancer
A Therapeutic & Competitive Insight
|
May 2007 |
£2105 |
40.5 % |
Bicalutamide: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
39 % |
Letrozole: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
39 % |
Gemcitabine: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
39 % |
Anastrozole: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
39 % |
Paclitaxel: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
38 % |
Irinotecan: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
38 % |
Gefitinib: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
38 % |
Avantogen Limited (formerly Australian Cancer Technology Limited) -Company Report
|
February 2008 |
£375 |
37.5 % |
Lapatinib: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
37.5 % |
Therapeutic Radiopharmaceuticals Markets
Sector Snapshot
|
December 2006 |
£250 |
36 % |
Prostate and Breast Cancer- New Treatments & Developmental Progress
|
March 2007 |
£2000 |
35.5 % |
Erlotinib: Pipeline™ Selector
Patent Report
|
Ongoing |
£210 |
35.5 % |
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
35 % |
Who's Developing What in New Cancer Drugs 2005?
|
September 2005 |
£495 |
35 % |
Analytical Tool: Breast Cancer R&D Comprehensive Guide
|
May 2007 |
£2105 |
34.5 % |
Analytical Tool - Targeted Therapeutics: Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
|
May 2007 |
£2105 |
34 % |
Breast Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
33.25 % |
Pancreatic Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
32.9 % |
Prostate Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
32.55 % |
Ovarian Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
32.55 % |
Breast Cancer
The Latest R&D Trends
|
February 2007 |
£1325 |
32.5 % |
Analytical Tool - Analysis of Colorectal Cancer R&D
The Complete Guide
|
September 2005 |
£2105 |
32.5 % |
Analytical Tool: Competitive Outlook on Cancer Vaccines
|
May 2007 |
£2105 |
32.5 % |
Cancer Drug Discoveries
What the Future Holds
|
August 2005 |
£1995 |
32.5 % |
Kidney Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
30.8 % |
Melanoma or Skin Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
30.8 % |
Liver Cancer Drug Pipeline Report
|
February 2008 |
£995 |
30.8 % |
Gastrointestinal (Stomach) Cancer Drug Pipeline Report
|
February 2008 |
£995 |
30.45 % |
Head and Neck Cancer Drug Pipeline Report
|
February 2008 |
£1495 |
30.1 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2340 |
29 % |
Analytical Tool: The Commercial Success of Cancer Therapeutic Antibodies
|
June 2006 |
£2105 |
28.5 % |
Cancer Market Top 20 Drugs
Supportive Care Grows the Cancer Market
|
January 2005 |
£8000 |
28.5 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£2340 |
28 % |
Analytical Tool: Analysis of Cancer Immunotherapy
The World Guide
|
May 2007 |
£3360 |
27.5 % |
Milagen, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
27.3 % |
Analytical Tool – Hematological Cancers
|
May 2007 |
£4040 |
26.5 % |
Optimizing Targeted Treatment in Cancer
Negotiating the Challenges to Success
|
September 2005 |
£1000 |
26 % |
Pricing And Reimbursement Series
NICE Its Impact On The UK Healthcare System And Beyond
|
September 2007 |
£2000 |
26 % |
Miraculins Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
25.2 % |
Cancer Stem Cells
Emerging Therapeutic, Diagnostic and Market Opportunities (2008)
|
June 2008 |
£1599 |
25.2 % |
Targeted Therapies in Oncology
|
May 2007 |
£100 |
25 % |
Targeted Diagnostics & Therapeutics, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
24.85 % |
Target Discovery, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
24.5 % |
Orion Genomics Product Pipeline Analysis
|
August 2008 |
£400 |
24.5 % |
Who's Developing What in New Cancer Drugs 2006?
|
November 2007 |
£495 |
23.8 % |
InterGenetics Incorporated Product Pipeline Analysis
|
August 2008 |
£400 |
23.8 % |
Targeted Therapies in Oncology
|
September 2007 |
£105 |
23.5 % |
World Cancer Market Yearbook 2005
|
December 2005 |
£495 |
23.45 % |
Monoclonal Antibody Therapy
Sector Snapshot
|
January 2007 |
£250 |
23 % |
Eu Paediatric Medicines Regulation
Boon or Burden?
|
January 2007 |
£1095 |
23 % |
Digene Corporation and Human Papillomavirus (HPV) Testing
|
January 2006 |
£150 |
23 % |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£2715 |
23 % |
DiaGenic ASA Product Pipeline Analysis
|
August 2008 |
£400 |
22.05 % |
Novo Nordisk Pharmaceutical Company Intelligence Report
Prospects to 2010
|
May 2007 |
£595 |
22 % |
Pulmonary Imaging: Contributions to Key Clinical Questions
|
June 2007 |
£140 |
22 % |
TriPath Imaging, Inc. and Cytology Diagnostics
|
February 2006 |
£150 |
22 % |
Glycominds Ltd. Product Pipeline Analysis
|
August 2008 |
£400 |
21.7 % |
Onconome, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
21.7 % |
Exiqon AS Product Pipeline Analysis
|
May 2008 |
£380 |
21.7 % |
Correlogic Systems, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
21.35 % |
Innovations in Cancer
Novel Therapeutics, New Diagnostics and Future R&D Strategies
|
February 2007 |
£1495 |
21.35 % |
The Cancer Market Outlook to 2012
|
January 2008 |
£1995 |
21.35 % |
Pipeline Insight: Therapeutic Cancer Vaccines
A turbulent path from bench to bedside
|
December 2006 |
£6000 |
21.35 % |
Wyeth Prospects to 2010
Performance, Products, Pipeline and Potential
|
July 2007 |
£595 |
21 % |
Gene Express, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
21 % |
A&G Pharmaceutical, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
21 % |
DNAPrint Genomics, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
20.65 % |
GUIDED THERAPEUTICS, INC. Product Pipeline Analysis
|
August 2008 |
£400 |
20.65 % |
Epigenetics and MicroRNA Diagnostics/Therapeutics 2008
|
May 2008 |
£2350 |
20.65 % |
Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey
|
January 1970 |
£7600 |
20.5 % |
Psoriasis and Psoriatic Arthritis
A Strategic Analysis of the Market in the United States
|
September 2006 |
£1765 |
20.5 % |
Pipeline Insight: Innovative Therapies
Targeted therapy, a clinical and commercial revolution?
|
August 2004 |
£6000 |
20.3 % |
Epigenomics AG Product Pipeline Analysis
|
August 2008 |
£400 |
20.3 % |
bioMerieux S.A. Product Pipeline Analysis
|
May 2008 |
£380 |
20.3 % |
Chronic Pain
|
June 2007 |
£74.99 |
20.3 % |
Stakeholder Insight: Breast Cancer
Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer
|
April 2005 |
£6000 |
19.95 % |
Stakeholder Opinions: Head and Neck Cancer
Innovatives to Change the Face of Treatment
|
November 2007 |
£2000 |
19.95 % |
Cancer Vaccines
Measuring Market Potential
|
October 2004 |
£745 |
19.6 % |
GRANT Life Sciences, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
19.6 % |
Analytical Tool - Targeted Therapeutics: Melanoma
|
July 2007 |
£2105 |
19.5 % |
Qiagen N.V. Product Pipeline Analysis
|
August 2008 |
£400 |
19.25 % |
Stakeholder Opinions: Gastric Cancer
Targeted Therapies Home In On a Neglected Tumor Type
|
March 2006 |
£2195 |
19.25 % |
MicroRNA Research Tools 2008
|
January 2008 |
£1540 |
19 % |
The Cancer Market Outlook to 2010
|
January 2005 |
£1495 |
18.9 % |
Epinex Diagnostics Incorporated Product Pipeline Analysis
|
August 2008 |
£400 |
18.9 % |
AdnaGen AG Product Pipeline Analysis
|
August 2008 |
£400 |
18.55 % |
Hereditary Breast Cancer
|
September 2007 |
£105 |
18.55 % |
Biogen Idec
Pipeline Products Performance Potential
|
March 2008 |
£595 |
18.5 % |
Hai Kang Life Corporation Limited Product Pipeline Analysis
|
August 2008 |
£400 |
18.2 % |
The Cancer Market Outlook to 2011
|
October 2006 |
£1495 |
18.2 % |
SpectRx, Inc. Product Pipeline Analysis
|
May 2008 |
£380 |
18.2 % |
Competitive Outlook on Apoptosis in Oncology
|
December 2006 |
£1325 |
17.85 % |
Poniard Pharmaceuticals Inc
Premium Company Profile
|
April 2008 |
£265 |
17.85 % |
Kyowa Hakko
Prospects to 2012
|
June 2007 |
£595 |
17.5 % |
Pipeline/Commercial Insight: Innovative Targeted Therapies
Smart Drugs' on Target for Increasing Growth
|
October 2005 |
£8695 |
17.15 % |
Peripheral Neuropathy and Neuropathic Pain, 2008
Current, Pipeline And Emerging Drugs For The Treatment Of Peripheral Neuropathy And Neuropathic Pain
|
January 2008 |
£1499 |
17.15 % |
Perceptronix Medical Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
17.15 % |
Worldwide Prescription Drug Market for Women’s Health
Now and Future 2004-2009
|
February 2001 |
£655 |
17.15 % |
CytoCore, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
16.8 % |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£2495 |
16.8 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
16.45 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
16.45 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
16.45 % |
Cancer Therapeutics Markets
|
May 2008 |
£1715 |
16.45 % |
Lymphoma
A Therapeutic & Competitive Insight
|
May 2006 |
£1325 |
16.45 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
16.45 % |
Aethlon Medical, Inc. Healthcare - Medical Equipment SWOT Report
|
May 2008 |
£63 |
16.45 % |
Cancer Therapeutics 2006
Market Dynamics and R&D Trends
|
December 2005 |
£1240 |
16.1 % |
Stakeholder Opinions: Ovarian Cancer
Growing importance as secondary indication for targeted therapies
|
July 2006 |
£2195 |
16.1 % |
World market for cancer vaccines 2007-2012
|
January 2007 |
£1999 |
16.1 % |
Pipeline Insight: Breast Cancer
Recent approvals increase pressure on pipeline candidates
|
April 2008 |
£6000 |
16.1 % |
Cancer Market Trends 2006 - 2010
Key market forecasts and growth opportunities
|
December 2006 |
£1050 |
16.1 % |
BSD Medical Corporation Product Pipeline Analysis
|
August 2008 |
£400 |
15.75 % |
Roche: Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
15.5 % |
China Sky One Medical, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
15.4 % |
China Medical Technologies, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
15.4 % |
Colorectal Cancer: Pipeline/Commercial Insight
Shaping the future dynamics of colorectal cancer management
|
October 2006 |
£8000 |
15.4 % |
Global Pipeline Review & Analysis of Hematological Malignancies
|
March 2007 |
£1665 |
15.4 % |
Gen-Probe Incorporated Product Pipeline Analysis
|
August 2008 |
£400 |
15.4 % |
Global Market for Adjunctive Therapies in Cancer, The
2nd Edition
|
April 2006 |
£1765 |
15.05 % |
Worldwide Market for In Vitro Diagnostic Tests
5th Edition
|
April 2006 |
£1970 |
15.05 % |
Emerging Cancer Vaccine Market, The
2nd Edition
|
November 2006 |
£1765 |
15.05 % |
Pharmaceutical Outsourcing Opportunities Post Launch
Contract Manufacturing, and Sales and Marketing,2nd Edition
|
September 2006 |
£1970 |
15.05 % |
World Market for Prescription Gastrointestinal Drugs, The
|
July 2006 |
£1765 |
15.05 % |
World Market for Prescription Orthopedic Drugs, The
|
October 2006 |
£1765 |
15.05 % |
World Market for Prescription Respiratory Drugs, The
|
October 2006 |
£1765 |
15.05 % |
World Market for Psychotherapeutic Drugs, The
|
January 2007 |
£1765 |
15.05 % |
Chinese Markets for Cancer Treatment Drugs
|
September 2005 |
£1985 |
15.05 % |
Medical and Biological Sensors and Sensor Systems
Markets, Applications, and Competitors Worldwide, 2nd Edition
|
May 2006 |
£1765 |
15.05 % |
HIV: A Strategic Analysis of Therapeutic and Testing Markets
|
March 2006 |
£1765 |
15.05 % |
The Impact of the Phase III Pipeline
Future Projections and Market Disruptions
|
March 2006 |
£1765 |
15.05 % |
World Market for Prescription Generic Drugs; The
5th Edition
|
April 2006 |
£1765 |
15.05 % |
Worldwide Market for Pediatric Drugs; The
2nd Edition
|
November 2005 |
£1765 |
15.05 % |
The Worldwide Market for Cancer Diagnostics
3rd Edition
|
March 2008 |
£2015 |
15.05 % |
Introgen Therapeutics Inc
Premium Company Profile
|
April 2008 |
£265 |
15.05 % |
Stakeholder Opinions: Bone Metastases
Impending Patent Expiries May Help Make or Break Newer Agents
|
March 2008 |
£2000 |
15.05 % |
World Market for Pain Management Drugs and Devices
2nd Edition
|
December 2006 |
£1765 |
15.05 % |
Daiichi Sankyo:
Pipeline • Products • Performance • Potential
|
June 2008 |
£595 |
15.05 % |
World Market for Respiratory Equipment; The
|
November 2005 |
£1765 |
15.05 % |
Daiichi Sankyo
Pipeline, Products, Performance, Potential
|
June 2008 |
£595 |
15.05 % |
Immunomodulators in Cancer Therapy
Emerging Products and Markets
|
August 2004 |
£1765 |
15.05 % |
Digene Corporation Product Pipeline Analysis
|
May 2008 |
£380 |
15.05 % |
Eli Lilly
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
15 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
15 % |
U.S. and Worldwide Monoclonal Antibody Medicine
Current Status and Future Trends
|
July 2008 |
£1260 |
14.7 % |
Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin
Oral therapy to take share in second-line hormone-refractory prostate cancer market
|
September 2006 |
£2195 |
14.7 % |
Pipeline Insight: Cancer Vaccines and Cell Therapies
Technical Know How Needs Translation Into Clinical and Commercial Rewards
|
April 2005 |
£6000 |
14.7 % |
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments
World Market
|
May 2007 |
£1005 |
14.7 % |
Vaccines Market Insight
Products, Pipelines & Market Outlook
|
January 2007 |
£1095 |
14.7 % |
Immunotherapy of Cancer
|
March 2007 |
£2410 |
14.35 % |
Emerging U.S. Biopharmaceutical Companies
New Drug R&D and Investment /Partnership Opportunities
|
April 2001 |
£545 |
14 % |
Molecular Diagnostics for Pharmacogenetic Testing
Testing volume, cost per test, and market potential
|
October 2004 |
£500 |
14 % |
Molecular Diagnostics for Infectious Disease Testing
Testing volume, cost per test, and market potential
|
October 2004 |
£500 |
14 % |
Pipeline Insight: Breakthrough Pain
Fast-acting players will capture majority market share
|
November 2006 |
£6000 |
14 % |
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
August 2006 |
£1325 |
14 % |
Commercial Insight Top 20 Cancer Therapeutics
|
July 2006 |
£8695 |
14 % |
Commercial and Pipeline Insight: Opioids
Short Acting and Anti-Abuse Technologies Set to Fragment and Grow The Market
|
March 2008 |
£7600 |
13.65 % |
SpectraScience, Inc. Healthcare
Medical Equipment SWOT Report
|
July 2008 |
£63 |
13.65 % |
Biomarkers: A Market Briefing
A Market Briefing
|
January 2007 |
£1005 |
13.65 % |
Cell Culture
The World Market for Media, Sera, and Reagents
|
January 2007 |
£1970 |
13.65 % |
Stakeholder Opinions: Gynecological Cancers
Niche opportunities in advanced disease
|
December 2006 |
£2000 |
13.65 % |
Cancer Personalized Medicine 2008
|
July 2008 |
£2425 |
13.65 % |
Stakeholder Insight: Pricing and Reimbursement in Oncology
Do payers believe oncology drugs offer good value?
|
December 2006 |
£6000 |
13.5 % |
Positron Emission Tomography Markets
|
December 2007 |
£990 |
13.3 % |
Pipeline Insight: Nociceptive Pain
Safety Profile Uppermost in Crowded Market
|
October 2004 |
£6000 |
13.3 % |
The Medical Device Market: Hong Kong
|
April 2005 |
£595 |
13.3 % |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1325 |
13.3 % |
Emerging Pharmaceutical Markets Globally
|
April 2008 |
£755 |
13 % |
Strategic Outlook on Protein Kinase Inhibitors in Oncology
|
February 2006 |
£1325 |
12.95 % |
Wellstar International, Inc. Healthcare
Medical Equipment SWOT Report
|
July 2008 |
£63 |
12.95 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£2340 |
12.6 % |
Commercial and Pipeline Insight: Psoriasis
Anti-TNF's lead another indication
|
December 2006 |
£8000 |
12.6 % |
IRIS International, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
12.6 % |
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma
Limited R&D activity provides opportunity for early-phase pipeline drugs
|
March 2007 |
£2000 |
12.6 % |
Siemens Medical Solutions Product Pipeline Analysis
|
August 2008 |
£400 |
12.6 % |
PET and SPECT-CT Imaging Technologies
Sector Snapshot
|
May 2006 |
£250 |
12.6 % |
The Medical Device Market: Malaysia
|
June 2007 |
£595 |
12.6 % |
Elekta AB
Strategic Analysis Profile
|
February 2008 |
£400 |
12.6 % |
TomoTherapy Incorporated Healthcare
Medical Equipment SWOT Report
|
July 2008 |
£63 |
12.6 % |
Cancer Vaccines: Aim and Shoot
|
May 2008 |
£1535 |
12.25 % |
Commercial Insight: Targeted Therapy Cancer Brands
High Growth Market Will See Eight New Blockbusters by 2017
|
July 2008 |
£7600 |
12.25 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£3510 |
12.25 % |
Siemens AG Product Pipeline Analysis
|
August 2008 |
£400 |
12.25 % |
FUJIFILM Medical Systems USA, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
12.25 % |
Convergence of Biomarkers and Diagnostics, The
Therapy Area Analyses, Key Products and Future Trends
|
April 2008 |
£1995 |
12.25 % |
The Medical Device Market
Denmark
|
May 2008 |
£595 |
12.25 % |
Monoclonal Antibody Therapies 2004
Entering A New Competitive Era
|
May 2004 |
£1115 |
11.9 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2340 |
11.9 % |
The Medical Device Market: Cuba
|
March 2008 |
£595 |
11.9 % |
The Medical Device Market
Taiwan
|
May 2008 |
£595 |
11.9 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2340 |
11.9 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£3510 |
11.9 % |
The Medical Device Market
Taiwan
|
May 2008 |
£595 |
11.9 % |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
|
November 2007 |
£2495 |
11.9 % |
Molecular Diagnostics - Revolution or Hype
|
May 2003 |
£2115 |
11.9 % |
Cancer Antibodies
Competitive Positioning for Success
|
June 2008 |
£1535 |
11.55 % |
Watson
Pharmavitae Generics Profile
|
September 2007 |
£2000 |
11.55 % |
The Pharmaceutical Market: Norway
|
March 2006 |
£595 |
11.55 % |
The Medical Device Market: Taiwan
|
March 2007 |
£595 |
11.55 % |
The Medical Device Market: Denmark
|
April 2007 |
£595 |
11.55 % |
The Medical Device Market
Czech Republic
|
May 2008 |
£595 |
11.55 % |
Innovations in Diagnostics
|
September 2006 |
£1495 |
11.55 % |
F. Hoffmann-La Roche Ltd.
|
